Displaying drugs 676 - 700 of 15308 in total
Chlormerodrin
Chlormerodrin is a mercurial compound with toxic side effects that was previously used as a diuretic. The radiolabeled form has been used as a diagnostic and research tool. It is no longer used and has been replaced with new classes of diuretic drugs.
Approved
Withdrawn
Matched Description: … The radiolabeled form has been used as a diagnostic and research tool. ... It is no longer used and has been replaced with new classes of diuretic drugs. …
Glutathione disulfide
A GLUTATHIONE dimer formed by a disulfide bond between the cysteine sulfhydryl side chains during the course of being oxidized.
Approved
Experimental
Investigational
Matched Iupac: … -2-[(carboxymethyl)carbamoyl]ethyl]disulfanyl}-1-[(carboxymethyl)carbamoyl]ethyl]carbamoyl}butanoic acid …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Latamoxef
Latamoxef is a broad- spectrum beta-lactam antibiotic similar in structure to the cephalosporins except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain cephalosporins. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.
Approved
Investigational
Matched Iupac: … methyl-1H-1,2,3,4-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid …
Matched Description: … It has been proposed especially for the meningitides because it passes the blood-brain barrier and for …
Matched Description: … It has been proposed especially for the meningitides because it passes the blood-brain barrier and for …
Oritavancin
Oritavancin is a glycopeptide antibiotic used for the treatment of skin infections. It was developed by The Medicines Company (acquired by Novartis). Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive bacteria that cause skin and skin structure infections. It boasts the option of...
Approved
Investigational
Matched Iupac: … }.0^{34,39}]pentaconta-3,5,8,10,12(48),14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylic acid …
Matched Description: … Marketed by Melinta Therapeutics, Kimyrsa offers effective and time-efficient treatment for skin and ... bacteria that cause skin and skin structure infections. ... It boasts the option of single-dose administration and has been proven as non-inferior to a full course …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Matched Description: … Marketed by Melinta Therapeutics, Kimyrsa offers effective and time-efficient treatment for skin and ... bacteria that cause skin and skin structure infections. ... It boasts the option of single-dose administration and has been proven as non-inferior to a full course …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Regadenoson
Regadenoson is an A2A adenosine receptor agonist that causes coronary vasodilation and used for myocardial perfusion imagining. Manufactured by Astellas and FDA approved April 10, 2008.
Approved
Investigational
Matched Description: … Manufactured by Astellas and FDA approved April 10, 2008. ... Regadenoson is an A2A adenosine receptor agonist that causes coronary vasodilation and used for myocardial …
Gadobutrol
Gadobutrol is a second-generation extracellular non-ionic macrocyclic GBCA (gadolinium-based contrast agent) used in magnetic resonance imaging (MRI) in adults and children older than 2 years of age. Due to its physicochemical properties, gadobutrol is
formulated at twice the gadolinium ion concentration compared to other GBCA and thus requires a lesser...
Approved
Matched Description: … macrocyclic GBCA (gadolinium-based contrast agent) used in magnetic resonance imaging (MRI) in adults and ... properties, gadobutrol is
formulated at twice the gadolinium ion concentration compared to other GBCA and …
Triclofos
Approved
Withdrawn
Matched Iupac: … (2,2,2-trichloroethoxy)phosphonic acid …
Matched Categories: … Hypnotics and Sedatives …
Matched Categories: … Hypnotics and Sedatives …
Lanthanum carbonate
Lanthanum carbonate is a phosphate binder marketed under the trade name Fosrenol by Shire Pharmaceuticals. It is a large pill that requires thorough chewing to avoid choking and other gastrointestinal adverse effects. It is used to treat elevated phosphate levels, primarily in patients with chronic kidney disease, by binding to...
Approved
Matched Description: … It is a large pill that requires thorough chewing to avoid choking and other gastrointestinal adverse ... phosphate levels, primarily in patients with chronic kidney disease, by binding to dietary phosphate and …
Matched Categories: … Drugs for Treatment of Hyperkalemia and Hyperphosphatemia …
Matched Categories: … Drugs for Treatment of Hyperkalemia and Hyperphosphatemia …
Mebutamate
Mebutamate is a sedative and anxiolytic drug with anti-hypertensive (blood pressure lowering) effects comparable to those of other barbiturates but is only around 1/3rd the potency of secobarbital as a sedative. Side effects include dizziness and headaches.
Approved
Matched Description: … Side effects include dizziness and headaches. ... Mebutamate is a sedative and anxiolytic drug with anti-hypertensive (blood pressure lowering) effects …
Urea C-14
Urea 14C is a urea molecule radiolabelled with a radioactive carbon-14. It is currently used for the Urea Breath Test (UBT) and is available as a rapid diagnostic test (marketed as PyTest) for the detection of Helicobacter pylori infections. H pylori is a common stomach bacteria that has been linked...
Approved
Matched Description: … the gastric epithelium and lumen and 14CO2 is absorbed into the blood and exhaled in the breath. ... Radiolabelled urea is available in two forms as 13C and 14C. ... peptic ulcers, stomach cancer, and gastric mucosa-associated lymphoid-tissue (MALT) lymphoma. …
Daprodustat
Daprodustat is a small-molecule hypoxia-inducible factor (HIF) prolyl hydroxylase (PHD) inhibitor that was developed by GSK.[A254167,A254162] Patients with CKD cannot induce erythropoietin (EPO) production in response to hypoxia or anemia. As a potent inhibitor of PHD1, PHD2 and PHD3 (≥ 1000-fold selectivity), daprodustat stabilizes cellular HIF1α and HIF2α and the induces...
Approved
Investigational
Matched Iupac: … 2-[(1,3-dicyclohexyl-2,4,6-trioxo-1,3-diazinan-5-yl)formamido]acetic acid …
Matched Description: … HIF1α and HIF2α and the induces erythropoiesis. ... As a potent inhibitor of PHD1, PHD2 and PHD3 (≥ 1000-fold selectivity), daprodustat stabilizes cellular ... [A254157] On October 2022, the FDA Cardiovascular and Renal Drugs Advisory Committee (CRDAC) supported …
Matched Categories: … Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …
Matched Description: … HIF1α and HIF2α and the induces erythropoiesis. ... As a potent inhibitor of PHD1, PHD2 and PHD3 (≥ 1000-fold selectivity), daprodustat stabilizes cellular ... [A254157] On October 2022, the FDA Cardiovascular and Renal Drugs Advisory Committee (CRDAC) supported …
Matched Categories: … Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …
Apronalide
Apronalide is approved in Japan. Apronalide has been withdrawn from the market in many other countries due to patient development of thrombocytopenic purpura .
Approved
Matched Categories: … Hypnotics and Sedatives …
Benzylpenicilloyl polylysine
Benzylpenicilloyl polylysine is used as a skin-testing reagent to detect immunoglobulin E antibodies in people with a history of penicillin allergy. The quantitation of in vitro IgE antibodies to the benzylpenicilloyl determinant is a useful tool for evaluating allergic subjects.
Approved
Velaglucerase alfa
Velaglucerase alfa is a gene-activated human recombinant glucocerebrosidase used for the treatment of Type 1 Gaucher disease, caused by a deficiency of the lysosomal enzyme glucocerebrosidase. Additionally, Velaglucerase alfa has also been investigated for use in Type 3 Gaucher disease.
Approved
Investigational
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism …
Imatinib
Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with...
Approved
Matched Description: … responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and ... [L42220]
Imatinib was approved on February 1st ,2001 by the FDA and November 7th, 2001 by the EMA …
Matched Categories: … Benzamides and benzamide derivatives ... Antineoplastic and Immunomodulating Agents …
Matched Categories: … Benzamides and benzamide derivatives ... Antineoplastic and Immunomodulating Agents …
Cilgavimab
SARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike (S) glycoprotein and host cell angiotensin-converting enzyme 2 (ACE2). Blocking the interaction between the receptor-binding domain (RBD) of the S1 subunit and ACE2 inhibits viral host cell entry; animal studies indicate that antibodies capable of...
Approved
Investigational
Matched Description: … modified through targeted amino acid substitutions to exhibit an extended (~85-day) half-life. ... The FDA and Health Canada advise healthcare providers to inform patients of this risk. ... The combination is co-packaged and available under the name EVUSHELD (formerly AZD7442). …
Matched Categories: … tixagevimab and cilgavimab ... Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …
Matched Categories: … tixagevimab and cilgavimab ... Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …
Tixagevimab
SARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike (S) glycoprotein and host cell angiotensin-converting enzyme 2 (ACE2). Blocking the interaction between the receptor-binding domain (RBD) of the S1 subunit and ACE2 inhibits viral host cell entry; animal studies indicate that antibodies capable of...
Approved
Investigational
Matched Description: … modified through targeted amino acid substitutions to exhibit an extended (~85-day) half-life. ... The FDA and Health Canada advise healthcare providers to inform patients of this risk. ... The combination is co-packaged and available under the name EVUSHELD (formerly AZD7442). …
Matched Categories: … tixagevimab and cilgavimab ... Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …
Matched Categories: … tixagevimab and cilgavimab ... Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …
Iobenguane
Synthetic guanethidine derivative that locates phaeochromocytomas and neuroblastomas. The radioisotope used can either be iodine-123 for imaging or iodine-131 for destruction of tissues that metabolize noradrenaline. Iodine 123 is a cyclotron-produced radionuclide that decays to Te 123 by electron capture. Images are produced by a I123 MIBG scintigraphy. FDA approved...
Approved
Investigational
Matched Description: … Synthetic guanethidine derivative that locates phaeochromocytomas and neuroblastomas. …
Matched Categories: … Indicators and Reagents …
Matched Categories: … Indicators and Reagents …
Insulin glulisine
Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the...
Approved
Matched Description: … B3 is replaced by lysine and the lysine at position B29 is replaced by glutamic acid. ... This recombinant hormone differs from native human insulin in that the amino acid asparagine at position ... and proteolysis among many other functions. …
Matched Categories: … Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins ... Insulins and Analogues for Injection, Fast-Acting ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Matched Categories: … Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins ... Insulins and Analogues for Injection, Fast-Acting ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Sotrovimab
Sotrovimab (VIR-7831), also known as GSK4182136, is a monoclonal antibody that can neutralize the SARS-CoV-2 virus. Sotrovimab was initially been granted emergency use authorization (EUA) to treat mild-to-moderate COVID-19 on May 26, 2021, based on interim results from a clinical trial, where sotrovimab was found to reduce the risk of...
Approved
Investigational
Matched Categories: … Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …
Trichlormethiazide
A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830)
Approved
Vet approved
Matched Categories: … trichlormethiazide and potassium ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics ... trichlormethiazide and potassium-sparing agents ... Low-Ceiling Diuretics and Potassium-Sparing Agents …
Trypsin
Trypsin is a serine protease that plays an essential role in protein hydrolysis and absorption in mammals. When converted from its zymogen trypsinogen, trypsin is available as an active peptide hydrolase (EC 3.4.21.4) form to cleave peptide chains, mainly at the carboxyl side of the amino acids lysine or arginine....
Approved
Vet approved
Matched Description: … Trypsin is a serine protease that plays an essential role in protein hydrolysis and absorption in mammals ... Therapeutic forms of trypsin is obtained from purified extracts of porcine or bovine pancreas and is ... nucleophilic attack is facilitated by the catalytic triad consisting of histidine-57, aspartate-102, and …
Matched Categories: … Enzymes and Coenzymes ... Blood and Blood Forming Organs ... Preparations for Treatment of Wounds and Ulcers …
Matched Categories: … Enzymes and Coenzymes ... Blood and Blood Forming Organs ... Preparations for Treatment of Wounds and Ulcers …
Beremagene geperpavec
Beremagene geperpavec is a live, replication-defective herpes simplex virus type 1 (HSV-1)-based vector therapy. Developed by Krystal Biotech, it was first approved by the FDA on May 19, 2023, for the treatment of wounds associated with dystrophic epidermolysis bullosa (DEB). DEB is caused by mutations in the COL7A1 gene that...
Approved
Matched Categories: … Cellular and Gene Therapy ... Preparations for Treatment of Wounds and Ulcers …
Iodohippurate sodium I-131
Approved
Nilotinib
Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant...
Approved
Investigational
Matched Description: … A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Displaying drugs 676 - 700 of 15308 in total